| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Identification of seven loci affecting mean telomere length and their association with disease.
|
Nat Genet
|
2013
|
3.87
|
|
2
|
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction.
|
Nat Genet
|
2010
|
3.55
|
|
3
|
New gene functions in megakaryopoiesis and platelet formation.
|
Nature
|
2011
|
3.14
|
|
4
|
Common variants near TERC are associated with mean telomere length.
|
Nat Genet
|
2010
|
2.98
|
|
5
|
Seventy-five genetic loci influencing the human red blood cell.
|
Nature
|
2012
|
2.77
|
|
6
|
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure.
|
J Am Coll Cardiol
|
2007
|
2.36
|
|
7
|
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
|
Eur Heart J
|
2013
|
2.32
|
|
8
|
Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study.
|
Eur J Epidemiol
|
2007
|
2.18
|
|
9
|
Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption.
|
Proc Natl Acad Sci U S A
|
2011
|
2.01
|
|
10
|
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders.
|
Nat Genet
|
2013
|
1.72
|
|
11
|
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
|
Arterioscler Thromb Vasc Biol
|
2010
|
1.68
|
|
12
|
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.
|
Circ Heart Fail
|
2012
|
1.67
|
|
13
|
Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia.
|
Cardiovasc Drugs Ther
|
2008
|
1.57
|
|
14
|
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.
|
Eur J Heart Fail
|
2012
|
1.51
|
|
15
|
Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction.
|
Stem Cells
|
2009
|
1.50
|
|
16
|
Left-dominant arrhythmogenic cardiomyopathy in a large family: associated desmosomal or nondesmosomal genotype?
|
Heart Rhythm
|
2012
|
1.46
|
|
17
|
Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anaemia.
|
Cardiovasc Res
|
2013
|
1.43
|
|
18
|
Telomere biology in healthy aging and disease.
|
Pflugers Arch
|
2009
|
1.41
|
|
19
|
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study.
|
Eur J Heart Fail
|
2003
|
1.41
|
|
20
|
Vitamin D status and outcomes in heart failure patients.
|
Eur J Heart Fail
|
2011
|
1.40
|
|
21
|
Galectin-3 mediates aldosterone-induced vascular fibrosis.
|
Arterioscler Thromb Vasc Biol
|
2012
|
1.37
|
|
22
|
Induction of kidney injury molecule-1 in homozygous Ren2 rats is attenuated by blockade of the renin-angiotensin system or p38 MAP kinase.
|
Am J Physiol Renal Physiol
|
2006
|
1.36
|
|
23
|
Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.
|
Am J Pathol
|
2011
|
1.30
|
|
24
|
Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms.
|
Hum Mol Genet
|
2009
|
1.25
|
|
25
|
The cardioprotective effects of metformin.
|
Curr Opin Lipidol
|
2011
|
1.19
|
|
26
|
Physiological interaction of heart and lung in thoracic irradiation.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.19
|
|
27
|
Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
|
Circ Heart Fail
|
2013
|
1.16
|
|
28
|
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
|
Cardiovasc Diabetol
|
2011
|
1.14
|
|
29
|
Liver X receptors alpha and beta regulate renin expression in vivo.
|
J Clin Invest
|
2005
|
1.13
|
|
30
|
The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.
|
J Steroid Biochem Mol Biol
|
2012
|
1.10
|
|
31
|
Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.
|
Am J Physiol Heart Circ Physiol
|
2011
|
1.10
|
|
32
|
Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience.
|
Eur J Heart Fail
|
2013
|
1.05
|
|
33
|
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).
|
Am Heart J
|
2011
|
1.04
|
|
34
|
Telomere length and psychological well-being in patients with chronic heart failure.
|
Age Ageing
|
2010
|
1.04
|
|
35
|
Aging, telomeres and heart failure.
|
Heart Fail Rev
|
2010
|
1.02
|
|
36
|
Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
|
Clin Res Cardiol
|
2012
|
1.01
|
|
37
|
Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial).
|
Am Heart J
|
2013
|
1.01
|
|
38
|
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
|
Cardiovasc Res
|
2010
|
1.00
|
|
39
|
Four genetic loci influencing electrocardiographic indices of left ventricular hypertrophy.
|
Circ Cardiovasc Genet
|
2011
|
0.99
|
|
40
|
Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing.
|
Cardiovasc Res
|
2008
|
0.99
|
|
41
|
New roles for renin and prorenin in heart failure and cardiorenal crosstalk.
|
Heart Fail Rev
|
2012
|
0.98
|
|
42
|
Telomere length of circulating leukocyte subpopulations and buccal cells in patients with ischemic heart failure and their offspring.
|
PLoS One
|
2011
|
0.97
|
|
43
|
Bone marrow dysfunction in chronic heart failure patients.
|
Eur J Heart Fail
|
2010
|
0.97
|
|
44
|
Possible association between telomere length and renal dysfunction in patients with chronic heart failure.
|
Am J Cardiol
|
2008
|
0.97
|
|
45
|
Circulating leukocyte and carotid atherosclerotic plaque telomere length: interrelation, association with plaque characteristics, and restenosis after endarterectomy.
|
Arterioscler Thromb Vasc Biol
|
2011
|
0.95
|
|
46
|
Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury.
|
Eur J Heart Fail
|
2004
|
0.95
|
|
47
|
Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial.
|
Cardiovasc Drugs Ther
|
2012
|
0.94
|
|
48
|
Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin-aldosterone system.
|
Lab Invest
|
2010
|
0.94
|
|
49
|
The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro.
|
PLoS One
|
2010
|
0.93
|
|
50
|
Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.
|
Am J Cardiol
|
2013
|
0.92
|
|
51
|
Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study.
|
Diabetes Care
|
2010
|
0.91
|
|
52
|
Telomere length and outcome in heart failure.
|
Ann Med
|
2010
|
0.90
|
|
53
|
Gaseous hydrogen sulfide protects against myocardial ischemia-reperfusion injury in mice partially independent from hypometabolism.
|
PLoS One
|
2013
|
0.90
|
|
54
|
Sex differences in new-onset heart failure.
|
Clin Res Cardiol
|
2014
|
0.89
|
|
55
|
A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study.
|
BMC Med Genet
|
2006
|
0.89
|
|
56
|
The emerging role of telomere biology in cardiovascular disease.
|
Front Biosci (Landmark Ed)
|
2010
|
0.89
|
|
57
|
Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial.
|
Heart
|
2011
|
0.88
|
|
58
|
Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models.
|
Physiol Genomics
|
2012
|
0.88
|
|
59
|
Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo.
|
Eur J Heart Fail
|
2010
|
0.88
|
|
60
|
Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study.
|
Clin Chem
|
2014
|
0.88
|
|
61
|
Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study.
|
Eur J Heart Fail
|
2011
|
0.87
|
|
62
|
AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes.
|
PLoS One
|
2013
|
0.86
|
|
63
|
Pharmacoepigenetics in heart failure.
|
Curr Heart Fail Rep
|
2010
|
0.86
|
|
64
|
Can critically short telomeres cause functional exhaustion of progenitor cells in postinfarction heart failure?
|
J Am Coll Cardiol
|
2007
|
0.86
|
|
65
|
Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-pro-endothelin-1.
|
Hypertension
|
2013
|
0.86
|
|
66
|
Renal dysfunction is associated with shorter telomere length in heart failure.
|
Clin Res Cardiol
|
2009
|
0.85
|
|
67
|
Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure.
|
Eur J Heart Fail
|
2010
|
0.85
|
|
68
|
Telomere biology in heart failure.
|
Eur J Heart Fail
|
2008
|
0.85
|
|
69
|
Animal models of cardiorenal syndrome: a review.
|
Heart Fail Rev
|
2012
|
0.84
|
|
70
|
Vitamin D deficiency: universal risk factor for multifactorial diseases?
|
Curr Drug Targets
|
2011
|
0.83
|
|
71
|
Erythropoietin in cardiac disease: new features of an old drug.
|
Eur J Pharmacol
|
2008
|
0.83
|
|
72
|
Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population.
|
Heart
|
2012
|
0.83
|
|
73
|
Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis.
|
Eur J Heart Fail
|
2012
|
0.83
|
|
74
|
A review on the putative association between beta-blockers and depression.
|
Heart Fail Clin
|
2011
|
0.83
|
|
75
|
The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
|
Expert Rev Mol Diagn
|
2014
|
0.82
|
|
76
|
Anemia in chronic heart failure: etiology and treatment options.
|
Curr Opin Cardiol
|
2008
|
0.82
|
|
77
|
Estradiol-induced, endothelial progenitor cell-mediated neovascularization in male mice with hind-limb ischemia.
|
Vasc Med
|
2009
|
0.82
|
|
78
|
Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin.
|
J Mol Med (Berl)
|
2010
|
0.82
|
|
79
|
DHRS7c, a novel cardiomyocyte-expressed gene that is down-regulated by adrenergic stimulation and in heart failure.
|
Eur J Heart Fail
|
2011
|
0.82
|
|
80
|
AKIP1, a cardiac hypertrophy induced protein that stimulates cardiomyocyte growth via the Akt pathway.
|
Int J Mol Sci
|
2013
|
0.81
|
|
81
|
Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system.
|
Hypertension
|
2008
|
0.80
|
|
82
|
The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
|
Eur J Heart Fail
|
2015
|
0.80
|
|
83
|
Biomarkers for risk prediction in acute decompensated heart failure.
|
Curr Heart Fail Rep
|
2014
|
0.79
|
|
84
|
Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
|
J Hypertens
|
2013
|
0.79
|
|
85
|
Regulation of the (pro)renin-renin receptor in cardiac remodelling.
|
J Cell Mol Med
|
2012
|
0.79
|
|
86
|
Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity.
|
Atherosclerosis
|
2013
|
0.79
|
|
87
|
Prognostic value of renin and prorenin in heart failure patients with decreased kidney function.
|
Am Heart J
|
2011
|
0.79
|
|
88
|
Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure.
|
Int J Cardiol
|
2002
|
0.78
|
|
89
|
Myostatin: an overlooked player in heart failure?
|
Eur J Heart Fail
|
2010
|
0.78
|
|
90
|
Heart failure, aging and beta-blockers: the need for more data on tolerability and efficacy.
|
Clin Res Cardiol
|
2008
|
0.78
|
|
91
|
Genome-wide meta-analyses of plasma renin activity and concentration reveal association with the kininogen 1 and prekallikrein genes.
|
Circ Cardiovasc Genet
|
2014
|
0.78
|
|
92
|
Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats.
|
Lab Invest
|
2003
|
0.77
|
|
93
|
Renal effects of long-term darbepoetin alpha treatment in hypertensive TGR(mRen2)27 rats.
|
J Renin Angiotensin Aldosterone Syst
|
2012
|
0.77
|
|
94
|
Statins in the treatment of heart failure.
|
Circ Heart Fail
|
2010
|
0.76
|
|
95
|
Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist.
|
Int J Cardiol
|
2013
|
0.76
|
|
96
|
Should erythropoietin treatment in chronic heart failure be haemoglobin targeted?
|
Eur J Heart Fail
|
2010
|
0.76
|
|
97
|
Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair.
|
Eur J Heart Fail
|
2013
|
0.76
|
|
98
|
Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients.
|
Clin Res Cardiol
|
2014
|
0.75
|
|
99
|
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.
|
Circulation
|
2017
|
0.75
|
|
100
|
Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA).
|
Eur J Heart Fail
|
2015
|
0.75
|
|
101
|
Brugada syndrome or Brugada electrocardiogram?
|
J Am Coll Cardiol
|
2009
|
0.75
|
|
102
|
ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
|
Cardiovasc Drugs Ther
|
2008
|
0.75
|
|
103
|
Letter by de Boer and van Veldhuisen regarding article, "Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)".
|
Circulation
|
2008
|
0.75
|
|
104
|
Stem cells in heart failure.
|
Eur J Heart Fail
|
2010
|
0.75
|
|
105
|
Low-dose digoxin in heart failure.
|
Int J Cardiol
|
2008
|
0.75
|
|
106
|
Erythropoiesis stimulation in acute ischemic syndromes.
|
Heart Fail Clin
|
2010
|
0.75
|
|
107
|
Meeting highlights from the 2010 European society of cardiology heart failure association winter meeting: translational heart failure research.
|
Eur J Heart Fail
|
2010
|
0.75
|
|
108
|
Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update.
|
Eur J Heart Fail
|
2011
|
0.75
|
|
109
|
The Nobel Prize for medicine for telomere biology and relevance to heart failure research.
|
Eur J Heart Fail
|
2009
|
0.75
|
|
110
|
New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475 000 Individuals.
|
Circ Cardiovasc Genet
|
2017
|
0.75
|
|
111
|
Plasma galectin-3 concentrations in patients with primary aldosteronism.
|
J Hypertens
|
2017
|
0.75
|